IV-MED 80

iVeena Delivery Systems

IVMED-80 is the first eye-drop, non-surgical, non-laser treatment for medical crosslinking of the cornea. The FDA granted orphan drug designation for IVMED-80 for the treatment of keratoconus in November 2017.

At-a-Glance
  • Mechanism of Action: It is believed that lysyl oxidases, a family comprising LOX and four LOX-like enzymes (LOXL1-4), catalyze the formation of collagen crosslinks and elastin and are implicated in the age-related corneal stiffening synonymous with keratoconus.
  • Dosage: One drop twice per day.

Details

FDA

Orphan Drug Designation

CE Mark

Not specified

Active Ingredients

Not specified

Application

Topical

Status

Prescription

Strength

Not specified

Company Information

Contact the company for additional information, availability, or pricing:

iVeena Delivery Systems

iveenamed.com

391 Chipeta Way

Salt Lake City, UT 84108